Decellularization reduces calcification while improving both durability and 1-year functional results of pulmonary homograft valves in juvenile sheep

Journal of Thoracic and Cardiovascular Surgery

Volumn 137, Issue 4, 2009, Pages

  Hopkins, Richard A ^a,c   Jones, Alyce Linthurst ^b   Wolfinbarger, Lloyd ^b   Moore, Mark A ^b   Bert, Arthur A ^a,c   Lofland, Gary K ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b LifeNet Health   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIFICATION; CONGENITAL HEART DISEASE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART RIGHT VENTRICLE OUTFLOW TRACT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PULMONARY VALVE; SHEEP;

EID: 62849115252     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2008.12.009     Document Type: Article

References (29)

1. Hilbert S.L., Luna R.E., Zhang J., et al. Allograft heart valves: the role of apoptosis-mediated cell loss. J Thorac Cardiovasc Surg 117 (1999) 454-462
2. Hopkins R.A. Bioprosthetic valves and laudable inflammation?. Circulation 114 (2006) 261-264
3. Messier R.H., Domkowski P.W., Aly H.M., et al. Adenine nucleotide depletion in cryopreserved human cardiac valves: the "stunned" leaflet interstitial cell population. Cryobiology 32 (1995) 199-208
4. Rhim C., and Niklason L.E. Tissue engineered vessels: cells to telomeres. Prog Pediatr Cardiol 21 (2006) 185-191
5. Fong P., Shin'oka T., Lopez-Soler R.I., and Breuer C. . The use of polymer based scaffolds in tissue-engineered heart valves. Prog Pediatr Cardiol 21 (2006) 193-199
6. Hopkins R. From cadaver harvested homograft valves to tissue-engineered valve conduits. Prog Pediatr Cardiol 21 (2006) 137-152
7. Jones M., Eidbo E.E., Hilbert S.L., Ferrans V.J., and Clark R.E. Anticalcification treatments of bioprosthetic heart valves: in vivo studies in sheep. J Card Surg 4 (1989) 69-73
8. Hilbert S.L., Barrick M.K., and Ferrans V.J. Porcine aortic valve bioprostheses: a morphologic comparison of the effects of fixation pressure. J Biomed Mater Res 24 (1990) 773-787
9. Hopkins R.A., and Hopkins R.A. Cardiac reconstructions with allograft tissues (2005), Springer-Verlag, New York
10. Hilbert S.L., Yanagida R., Souza J., et al. Prototype anionic detergent technique used to decellularize allograft valve conduits evaluated in the right ventricular outflow tract in sheep. J Heart Valve Dis 13 (2004) 831-840
11. Ketchedjian A., Kreuger P., Lukoff H., et al. Ovine panel reactive antibody assay of HLA responsivity to allograft bioengineered vascular scaffolds. J Thorac Cardiovasc Surg 129 (2005) 159-166
12. Haycock G.B., Schwartz G.J., and Wisotsky D.H. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr 93 (1978) 62-66
13. Koolbergen D.R., Hazekamp M.G., de Heer E., et al. The pathology of fresh and cryopreserved homograft heart valves: an analysis of forty explanted homograft valves. J Thorac Cardiovasc Surg 124 (2002) 689-697
14. Simon P., Kasimir M.-T., Rieder E., and Weigel G. . Tissue Engineering of heart valves-immunologic and inflammatory challenges of the allograft scaffold. Prog Pediatr Cardiol 21 (2006) 161-165
15. Christenson J.T., and Kalangos A. Blood group antigenicity and clinical durability of cryopreserved homografts. Prog Pediatr Cardiol 21 (2006) 227-231
16. Ketchedjian A., Jones A.L., Krueger P., et al. Recellularization of decellularized allograft scaffolds in ovine great vessel reconstructions. Ann Thorac Surg 79 (2005) 888-896
17. Shaddy R.E., Thompson D.D., Osborne K.A., Hawkins J.A., and Fuller T.C. Persistence of human leukocyte antigen (HLA) antibodies after one year in children receiving cryopreserved valved allografts. Am J Cardiol 80 (1997) 358-359
18. Hoekstra F., Witvliet M., Knoop C., et al. Donor-specific anti-human leukocyte antigen class I antibodies after implantation of cardiac valve allografts. J Heart Lung Transplant 16 (1997) 570-572
19. Christenson J.T., Vala D., Sierra J., Beghetti M., and Kalangos A. Blood group incompatibility and accelerated homograft fibrocalcifications. J Thorac Cardiovasc Surg 127 (2004) 242-250
20. Hoekstra F.M., Witvliet M., Knoop C.Y., et al. Immunogenic human leukocyte antigen class II antigens on human cardiac valves induce specific alloantibodies. Ann Thorac Surg 66 (1998) 2022-2026
21. Rajani B., Mee R.B., and Ratliff N.B. Evidence for rejection of homograft cardiac valves in infants. J Thorac Cardiovasc Surg 115 (1998) 111-117
22. Kasimir M.T., Rieder E., Seebacher G., et al. Decellularization does not eliminate thrombogenicity and inflammatory stimulation in tissue-engineered porcine heart valves. J Heart Valve Dis 15 (2006) 278-286
23. Vogt P.R., Stallmach T., Niederhauser U., et al. Explanted cryopreserved allografts: a morphological and immunohistochemical comparison between arterial allografts and allograft heart valves from infants and adults. Eur J Cardiothorac Surg 15 (1999) 639-644
24. Simon P., Kasimir M.T., Seebacher G., et al. Early failure of the tissue engineered porcine heart valve SYNERGRAFT(TM) in pediatric patients. Eur J Cardiothorac Surg 23 (2003) 1002-1006
25. De Visscher G., Blockx H., Meuris B., et al. Functional and biomechanical evaluation of a completely recellularized stentless pulmonary bioprosthesis in sheep. J Thorac Cardiovasc Surg 135 (2008) 395-404
26. Schmidt D., Stock U.A., and Hoerstrup S.P. Tissue engineering of heart valves using decellularized xenogeneic or polymeric starter matrices. Philos Trans R Soc Lond B Biol Sci 362 (2007) 1505-1512
27. Taylor P.M., Cass A.E.G., and Yacoub M.H. Extracellular matrix scaffolds for tissue engineering heart valves. Prog Pediatr Cardiol 21 (2006) 219-225
28. Lichtenberg A., Breymann T., Cebotari S., and Haverich A. Cell seeded tissue engineered cardiac valves based on allograft and xenograft scaffolds. Prog Pediatr Cardiol 21 (2006) 211-217
29. Bechtel J.F., Stierle U., and Sievers H.H. Fifty-two months' mean follow up of decellularized SynerGraft-treated pulmonary valve allografts. J Heart Valve Dis 17 (2008) 98-104